Get the Stockscreener App
30.95
0.13%
-0.04
After Hours:
30.95
Alkermes Plc stock is traded at $30.95, with a volume of 1.05M.
It is down -0.13% in the last 24 hours and up +3.37% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$30.99
Open:
$31.09
24h Volume:
1.05M
Relative Volume:
0.55
Market Cap:
$5.11B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
15.87
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
+3.17%
1M Performance:
+3.37%
6M Performance:
+4.95%
1Y Performance:
+11.37%
1-Day Range:
$30.70
$31.10
1-Week Range:
$29.85
$31.68
52-Week Range:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
30.95 | 5.12B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
142.77 | 64.42B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.46 | 45.95B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
8.82 | 39.14B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.07 | 22.90B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
456.84 | 20.50B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Substance Abuse Treatment Market Size, Growth Analysis 2031 - openPR.com
Is Alkermes plc (8AK) stock at risk of policy regulationGold Moves & Daily Entry Point Alerts - newser.com
Is Alkermes plc reversing from oversold territoryTrade Risk Assessment & Reliable Breakout Stock Forecasts - newser.com
Is Alkermes plc (8AK) stock cheap vs fundamentalsWeekly Trading Summary & AI Optimized Trade Strategies - newser.com
Will Alkermes plc (8AK) stock hit Wall Street targetsVolume Spike & Comprehensive Market Scan Insights - newser.com
Technical analysis overview for Alkermes plc stockMarket Weekly Review & Fast Exit/Entry Strategy Plans - newser.com
Alkermes Plc Experiences Evaluation Revision Amidst Mixed Market Signals and Performance Trends - Markets Mojo
Alkermes sued over alleged scheme to block generic Vivitrol - Reuters
Is Alkermes plc a good long term investmentMACD Trading Signals & Investor Community Interactions - earlytimes.in
Will Alkermes plc (8AK) stock benefit from Fed rate cuts2025 Market Overview & Comprehensive Market Scan Insights - newser.com
Can Alkermes plc stock deliver strong Q4 earningsPortfolio Growth Summary & Fast Gaining Stock Reports - newser.com
How cyclical is Alkermes plc (8AK) stock compared to rivals2025 Trade Ideas & Free AI Powered Buy and Sell Recommendations - newser.com
What candlestick patterns are forming on Alkermes plcJuly 2025 Patterns & Fast Gain Stock Trading Tips - newser.com
Alkermes Plc Hits Day High with Strong 10.58% Intraday Surge - Markets Mojo
Alkermes (ALKS) Added to Wells Fargo's Tactical Ideas List - GuruFocus
What analysts say about Alkermes plc 8AK stockPrice-to-Earnings Ratio Insights & Budget Friendly Capital Growth - earlytimes.in
What drives Alkermes plc stock priceMarket Breadth Indicators & Explosive Profit Trading - earlytimes.in
Alkermes : Corporate Responsability Report - MarketScreener
Alkermes plc (ALKS) Stock Analysis: Exploring a 49.54% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
U.S. Buprenorphine Market Set for Dynamic Growth with Key - openPR.com
How Investors May Respond To Alkermes (ALKS) Phase 2 Alixorexton Narcolepsy Trial Outperformance - Sahm
Alkermes upgraded at RBC Capital Markets ahead of key catalyst - MSN
Is Alkermes' (ALKS) Narcolepsy Drug Breakthrough Shifting Its Investment Narrative? - Yahoo Finance
Alkermes Plc Experiences Evaluation Revision Amid Mixed Market Performance Indicators - Markets Mojo
Alkermes' Stock Dip on Narcolepsy Data Seen as Buying Opportunity, RBC Says - MarketScreener
Alkermes stock upgraded at RBC Capital Markets (ALKS:NASDAQ) - Seeking Alpha
Alkermes (NASDAQ:ALKS) Shares Gap Up After Analyst Upgrade - MarketBeat
Alkermes (NASDAQ:ALKS) Upgraded by Royal Bank Of Canada to "Outperform" Rating - MarketBeat
RBC Capital Upgrades ALKS: Price Target Raised to $44 | ALKS Sto - GuruFocus
RBC Capital Upgrades Alkermes (ALKS) - Nasdaq
RBC Capital Upgrades Alkermes to Outperform From Sector Perform, Adjusts PT to $44 From $42 - MarketScreener
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):